Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7814.042 | 0.9967 | 0.9921 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7814.042 | 0.8949 | 0.7528 | 0.8414 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7816.042 | 0.9368 | 0.8648 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7816.042 | 1.0127 | 1.0273 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7816.042 | 0.9940 | 0.9872 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7816.042 | 0.9692 | 0.9341 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7816.042 | 1.0890 | 1.1913 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7816.042 | 1.0847 | 1.1820 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7816.042 | 1.0956 | 1.2056 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7816.042 | 1.0683 | 1.1467 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7816.042 | 1.0002 | 1.0005 | 0.9332 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9254.124 | 1.1876 | 1.4751 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9254.124 | 1.1370 | 1.3449 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9254.124 | 1.1398 | 1.3522 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9254.124 | 1.0881 | 1.2207 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9254.124 | 1.0584 | 1.1458 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9254.124 | 1.1367 | 1.3443 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9254.124 | 0.9806 | 0.9521 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9254.124 | 1.0755 | 1.1887 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9254.124 | 0.8954 | 0.7439 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9258.026 | 1.0214 | 1.0765 | 0.5632 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9258.026 | 1.0592 | 1.2149 | 0.5632 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9258.026 | 0.9357 | 0.7775 | 0.5632 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9258.026 | 1.0445 | 1.1606 | 0.5632 | |
| HCC1395 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9258.026 | 1.0270 | 1.0967 | 0.5632 |